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Abstract: Novel and alternative options are being adopted to combat the initiation and progression
of human cancers. One of the approaches is the use of molecules isolated from traditional medicinal
herbs, edible dietary plants and seeds that play a pivotal role in the prevention/treatment of
cancer, either alone or in combination with existing chemotherapeutic agents. Compounds that
modulate these oncogenic processes are potential candidates for cancer therapy and may eventually
make it to clinical applications. Diosgenin is a naturally occurring steroidal sapogenin and is one
of the major bioactive compounds found in dietary fenugreek (Trigonella foenum-graecum) seeds.
In addition to being a lactation aid, diosgenin has been shown to be hypocholesterolemic, gastro-
and hepato-protective, anti-oxidant, anti-inflammatory, anti-diabetic, and anti-cancer. Diosgenin
has a unique structural similarity to estrogen. Several preclinical studies have reported on the
pro-apoptotic and anti-cancer properties of diosgenin against a variety of cancers, both in in vitro and
in vivo. Diosgenin has also been reported to reverse multi-drug resistance in cancer cells and sensitize
cancer cells to standard chemotherapy. Remarkably, diosgenin has also been reported to be used
by pharmaceutical companies to synthesize steroidal drugs. Several novel diosgenin analogs and
nano-formulations have been synthesized with improved anti-cancer efficacy and pharmacokinetic
profile. In this review we discuss in detail the multifaceted anti-cancer properties of diosgenin that
have found application in pharmaceutical, functional food, and cosmetic industries; and the various
intracellular molecular targets modulated by diosgenin that abrogate the oncogenic process.
Keywords: diosgenin; steroidal sapogenins; anti-cancer; apoptosis; oncogenic; metastasis
1. Introduction
Cancer is a complex and heterogeneous disease that afflicts men and women worldwide; it is
expected to increase due to human lifestyle changes and a rapidly aging population [1]. Hanahan
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and Weinberg’s proposed hallmarks of cancer are widely accepted towards understanding the
biology of cancer cells, through a multi-stage and progressive process [2–6]. These hallmarks include
sustained proliferation of cells, constitutive activation of pro-survival transcription factors, deregulated
cellular functions, evading cell death signals and growth suppressors, an increased pro-inflammatory
tumor microenvironment, camouflaging against immune cell destruction, promoting angiogenesis,
activating cell movement from the primary site and metastasis, enabling replicative immortality,
and finally, severe genome instability [2,3,5–10]. In addition, several deregulated cellular signaling
networks underlying the above hallmarks have been extensively investigated in pre-clinical and
clinical drug development [3,4,11–18]. In spite of detailed information of these semi-synthetic and
synthetic anti-cancer agents, they only provide limited therapeutic advantages to patients due to
highly toxic unwanted side effects and the development of chemoresistance [19–21]. Emerging
approaches should include the identification of novel drug targets that are very effective in inhibiting
the growth of cancer cells, while exhibiting fewer adverse effects. Natural products are a good
source of compounds with novel chemical structures that are effective and less toxic [18,22–27]. High
throughput technologies should be exploited for the screening of a large library of compounds for
their anti-cancer activities [28–30]. The mainstream of United States Food and Drug Administration
(US FDA)-approved compounds divulge that natural products and their derivatives occupy one-third
of all novel drugs [22–24,31]. These natural compounds, in general, show multi-targeted effects and
can modulate several oncogenic transcription factors that block the tumor microenvironment targets
that usually sustain tumor growth [22,27,32]. These compounds can also be classified as cytotoxic or
cytostatic compounds [30]. Therefore, many secondary metabolites and pure molecules isolated from
herbs, spices, dietary fruits and vegetables, and even marine sources have been explored [33–35].
Several novel bioactive molecules have been found in various edible cereals, pulses, roots, and
in several parts of medicinal plants. Fenugreek (Trigonella foenum-graecum) belongs to the family
Leguminosae and is considered a traditional medicinal herb that is commonly used in India, China,
Thailand, and South-East Asian countries; it is also cultivated in the Mediterranean region and Northern
Africa [36–41]. Fenugreek seeds, shoots and leaves are used in Indian curry preparation as a condiment.
Bibliometric data indicates that fenugreek extract has several pharmacological properties, such as
being hypocholesterolemic, a lactation aid, antibacterial, a gastric stimulant, anti-anorexic, antidiabetic,
galactogogic, hepatoprotective, and anti-cancer both in in vitro and in vivo studies [40–43]. Fenugreek
seed extract contains several bioactive molecules in various classes of compounds, such as saponins,
flavonoids, coumarins, and alkaloids that target several molecules involved in inflammation and cancer
cell proliferation, invasion, migration, angiogenesis, and metastasis [40]. Sapogenins are a class of
compounds that widely occur in natural products in their glycoside form and promote general healthy
living. Among these compounds, steroidal sapogenins (otherwise known as spirostans) are the most
potent bioactive compounds isolated from natural product sources [44,45]. Steroidal sapogenins exhibit
ubiquitous pharmacological properties and the majority of them demonstrate anti-cancer activity
in vitro and in pre-clinical animal models. Several clinical trials have been conducted with fenugreek
seed extract, they are either completed or ongoing; however, diosgenin anti-cancer trials are yet
to start [36,41]. Diosgenin is the most abundant steroidal sapogenin in fenugreek seeds. Fujii and
Matsukawa isolated and identified diosgenin from Dioscorea tokoro Makino in 1935 [41,46] (Figure 1).
Diosgenin is a phytosteroidal saponin and a major bioactive compound found in the seeds of T.
foenum-graecum, commonly known as fenugreek, and in the roots of wild yam (Dioscorea villosa) [36,40,
41,47,48]. Interestingly, diosgenin is also found in high levels in numerous plant species including Costus
speciosus, Smilax menispermoidea, species of Paris, Aletris and Trillum, and in species of Dioscorea [41,49,50].
The steroidal saponin, diosgenin, is biosynthesized from cholesterol. Cholesterol is formed from
lanosterol and catalysed by the cytochrome P450 system. Several other routes of synthesis have been
identified, such as from squalene-2,3-oxide in two ways: From cycloartenol through the formation
of sitosterol [51] and from lanosterol via cholesterol [52]. Several studies have demonstrated the
diverse biological activities of diosgenin, such as hypolipidemic, anti-inflammatory, anti-proliferative,
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hypoglycemic activity, and as a potent anti-oxidant [44]. In addition, diosgenin inhibited cancer cell
proliferation and induced apoptosis in a variety of cancer cell lines including colorectal, hepatocellular,
breast, osteosarcoma, and leukemia [53–55]. The primary mechanism of action of diosgenin is through
the modulation of multiple cell signaling pathways that play prominent roles in cell-cycle regulation,
differentiation, and apoptosis [56]. Remarkably, pharmaceutical companies use diosgenin as a principal
precursor compound for the manufacturing of several steroidal drugs [48]. Diosgenin is also an attractive
molecule with multifaceted properties that has found application in pharmaceutical, functional food,
and cosmetic industries. In this review we provide an in-depth evaluation of literature on diosgenin
and its pharmacodynamics and pharmacokinetics, and discuss several of its novel derivatives and
nanoformulations that increase its bioavailability and therapeutic efficacy. Diosgenin, over the years,
has provided abundant data on the prevention and treatment of various inflammation-driven diseases,
including cancers [36] (Figure 2).
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2. Fenugreek Seed Bioactive Compounds
Fenugreek contains several chemical constituents, such as alkaloids, steroidal sapogenins,
saponins, flavonoids, lipids, amino acids, and carbohydrates. Diosgenin is a major bioactive steroidal
sapogenin in the fenugreek seed, which is reported to have chemopreventive and therapeutic effects
against inflammation and chronic inflammation-driven cancers in preclinical in vitro and in vivo
models of cancer [36,57]. Table 1 illustrates the major constituents of fenugreek seeds and leaves.
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Table 1. Main phytochemical constituents of fenugreek (T. foenum-graecum).
Class of Compounds Phytochemical Constituents Reference
Steroidal sapogenins Diosgenin, Yamogenin, Smilagenin, Sarsasapogenin, Tigogenin,Neotigogenin, Gitogenin, Yuccagenin, Saponaretin [40]
Flavonoids Quercetin, Rutin, Vitexin, Isovitexin [40]
Saponins Graecunins, Fenugrin B, Fenugreekine, Trigofoenosides A–G [40]
Alkaloids Trimethylamine, Neurin, Trigonelline, Choline, Gentianine,Carpaine, and Betain [40]
Fibers Gum, Neutral detergent fiber [40]
Lipids
Lipids, Triacylglycerols, Diacylglycerols, Monoacylglycerols,
Phosphatidylcholine, Phosphatidylethanolamine,
Phosphatidylinositol, Free fatty acids
[40]
Others Coumarin, Amino acids, Vitamins, Minerals. 28% Mucilage;22% Proteins; 5% of a stronger swelling, Bitter fixed oil [40]
3. In Vitro Anti-Cancer Effects of Diosgenin
Diosgenin, the major steroidal sapogenin in the fenugreek seed, has been shown to potently
suppress constitutively-activated pro-inflammatory and pro-survival signaling pathways in a variety
of cancer cells, and induced apoptosis [58]. Some of the earlier studies by Shishodia and Aggarwal [58]
reported that diosgenin abrogated TNF-α-induced NF-κB activation and suppressed osteoclastogenesis
in RAW 264.7 macrophage cells [58]. In Her-2 positive breast cancer cells, diosgenin inhibited the
expression of AKT, mTOR, JNK and their associated pro-survival signaling pathways, and induced
apoptosis in these cells [53]. In another study by Li et al., they reported that diosgenin could inactivate
the STAT3 signaling pathway in hepatocellular carcinoma (HCC) cells, by inhibiting intracellular
signaling molecules such as c-SRC, JAK1, and JAK2 (Figure 3). Diosgenin also suppressed STAT3
transcriptional activity and the expression of its downstream gene products involved in proliferation,
invasion and metastasis. In addition, diosgenin sensitized HCC cells to doxorubicin and paclitaxel,
and synergistically augmented apoptosis, thereby suggesting that diosgenin is a potential bioactive
compound for the treatment of HCC and other cancers [54]. Diosgenin inhibited proliferation,
AKT and JNK in a dose- and time-dependent manner and induced caspase-dependent apoptosis
in A431 and Hep2 skin squamous cell carcinoma cells [59]. HT-29 colon cancer cells have been
reported to be resistant to TRAIL-induced apoptosis. Diosgenin was shown to sensitize the HT-29
colon cancer cell to TRAIL. In addition, it potently suppressed cell proliferation and induced
apoptosis by suppressing the p38/MAPK signaling pathway and the overexpression of DR5 [60].
Furthermore, Romero-Hernandez et al. [61] demonstrated that diosgenin-derived thio(seleno)ureas
and glycomimetics, bearing a 1,2,3-triazolyl tether on C-3, showed more potent anti-cancer activity
against MDA-MB-231 and MCF-7 breast cancer cells, HepG2 hepatocellular carcinoma cells, and
induced apoptosis, compared to its parent compound diosgenin [61]. In another study, diosgenin
conjugated to methotrexate was found to be more potent in inhibiting the growth of transport-resistant
breast cancer cells and dihydrofolate reductase (enzyme involved in DNA synthesis), compared to
the parent diosgenin [62]. In chronic myeloid leukemia cells, diosgenin-induced autophagy inhibited
the mTOR signaling pathway and induced apoptotic cell death [63]. Diosgenin induced cytotoxicity
and significantly inhibited the growth and proliferation of MCF-7 breast cancer cells in a dose- and
time-dependent manner. Diosgenin was also shown to inhibit N-nitroso-N-methylurea-induced breast
cancer in rats [64].
Of several factors that contribute to the sustained growth and proliferation of tumors, one important
factor is the abundant neovascularization or formation of new micro blood vessels at the tumor site,
or within the tumor. This process is also known as tumor angiogenesis. Thus, the formation of new
blood vessels in tumors actively supplies the essential nutrients and growth factors that allow tumors to
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acquire the ability to reject chemotherapeutic drugs and develop chemoresistance [27,65–68]. Diosgenin
is also a potent inhibitor of cancer cell invasion, migration, and tumor-associated angiogenesis [27,69].
He et al., reported that diosgenin inhibited the invasion and migration of triple-negative breast cancer
cells and was associated with the concomitant suppression of actin polymerization, phosphorylation of
Vav2, and activation of Cdc42 oncoprotein expression. These proteins have been shown to be involved
in the initiation of cancer cells’ invasive and migratory potential [70]. Similarly, diosgenin was found
to inhibit PC3 androgen-independent prostate cancer cell invasion and migration. The inhibitory
effect was mediated by the downregulation of matrix metalloproteinase (MMP)-2 and MMP-9, the key
enzymes in matrix degradation and stroma invasion. Furthermore, diosgenin also downregulated
the tissue inhibitors of metalloproteinase (TIMP)-2, vascular endothelial growth factor (VEGF),
extracellular regulated kinase (ERK), Janus kinase (JNK), phosphotidyl-inositol-3 kinase/protein
kinase B (PI3K/AKT), and NF-κB transcriptional activity [56]. In addition, diosgenin was reported
to inhibit the expression of E-cadherin, integrin 5a and 6b, invasion, migration, and angiogenesis in
hypoxia-sensitive BGC-823 gastric cancer cells [71]. Diosgenin was reported to inhibit proliferation
of ER-positive MCF-7 breast cancer cells by the upregulation of the p53 tumor suppressor gene and
activation of caspase 3, while it downregulated BCL2 in ER negative MDA-MB-231 triple-negative
breast cancer cells [72]. Diosgenin, either alone, or in combination with thymoquinone, inhibited A431
and Hep2 squamous cell carcinoma cell proliferation, increased the Bax/Bcl2 ratio, and induced caspase
3-mediated apoptosis [59] (Table 2). The potential effect of diosgenin on NF-κB and STAT3 signaling
pathways in tumor cells, is shown in Figure 3.
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Table 2. In vitro anti-cancer effects of diosgenin.
Cancer model Cell Lines Diosgenin Dose Molecular Target References
Breast carcinoma
Estrogen receptor positive and estrogen receptor
negative human breast cancer MCF-7 and MDA 231 cells 20 µM and 30 µM
Inhibition of cell proliferation
Induces apoptosis [72]
MDA-MB-231 breast cancer cells 20 µM, 40 µM,and 60 µM Downregulation of Bcl2 [57]
Her2 over-expressing breast cancer cells 5–20 µM Modulation of Akt, mTOR, and JNKphosphorylation [53]
MCF-7 breast cancer cells 20 µM and 40 µM Upregulation of p53 tumor suppressor gene [73]
Hepatocellular carcinoma C3A, HUH-7, and HepG2 cells 50 µM and 100 µM
Downregulation of STAT3 signaling pathway
Upregulates SH-PTP2 expression
Induces apoptosis
Potentiates the apoptotic effects of doxorubicin
and paclitaxel
[54]
Prostate carcinoma PC3 cells 5 µM, 10 µM,and 20 µM
Downregulates NF-κB signaling pathway
Inhibits matrix metalloproteinases
Inhibits invasion and migration of cells
[56]
Osteosarcoma
1547 cells 40 µM, 80 µM,and 100 µM
Inhibits cell proliferation
Induces apoptosis [55]
1547 cells 40 µM
Inhibits cell proliferation
Induces apoptosis
Upregulation of p53 tumor suppressor gene
[74]
Human erythroleukemia
HEL cells, K562 cells 40 µM Inhibits NF-κB signaling pathway [75]








M4Beu cells 40 µM
Inhibits cell proliferation
Induces caspase-3 dependent apoptosis
Upregulates p53 tumor suppressor gene
[77]
Human cancer cells
Human epithelial carcinoma cell line (A431), human
NSCLC cell line (A549), human ovarian cancer cell line
(A2780), Human erythroleukemia (K562) and Dukes’
type C, colorectal adenocarcinoma (HCT-15)
10 mmol/L Induces apoptosis via mitochondrialdependent pathway [78]
Multiple myeloma (U266), leukemia (U937), and breast
cancer (MCF-7) 50 µM and 100 µM Inhibits NF-κB signaling pathway [58]
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4. In Vivo Anti-Cancer Effects of Diosgenin
In addition to in vitro inhibition of cancer cell proliferation by dietary fenugreek seeds and
its bioactive constituent diosgenin, several studies have provided evidence that diosgenin is
a potent inhibitor of tumor growth in vivo in rodent models of cancer. In a rat colorectal tumor
model, administration of diosgenin, given during the promotional stage, reduced azoxymethane
(AOM)-induced colonic aberrant crypt foci formation [79]. Similarly, Malisetty et al., showed
that diosgenin, at a dose of 15 mg/kg, significantly suppressed both the incidence and invasive
potential of AOM-induced rat colon adenocarcinoma mass by 60% and colon tumor multiplicity
(adenocarcinomas/rat) by 68% [80]. However, in the murine model of AOM/dextran sodium
sulfate-induced colon aberrant crypt foci, diosgenin at doses of 20, 100 and 200 mg/kg b.w. in the
diet did not reduce adenocarcinoma mass; nonetheless, a significant reduction in tumor multiplicity
was observed with all three doses tested [81]. In another study, diosgenin (at a dose of 10 mg/kg
b.w. administered intra-tumorally) significantly inhibited the growth of MCF-7 and MDA-MB-231
human breast cancer xenografts in mice [72]. In another study using inbred T739 mice, diosgenin was
shown to significantly inhibit the growth of mouse LA795 lung adenocarcinoma tumors by 33.94% [82].
Diosgenin, at a dose of 80 mg/kg administered by oral gavage, was reported to inhibit the growth
of oral tumors in a DMBA-induced hamster buccal pouch model [64]. Diosgenin, in combination
with thymoquinone, exhibited significant tumor growth inhibition in a mice xenograft model [59].
Therefore, diosgenin modulates multiple targets and suppresses tumor growth in preclinical models
of cancer. However, diosgenin’s poor solubility in organic solvents and its lack of bioavailability
greatly hinder its translational process as a therapeutic compound. Further clinical trials are required
to evaluate its potential either as a preventive or therapeutic anti-cancer agent.
5. Semisynthetic Derivatives of Diosgenin That Exhibit Anti-Cancer Activity
Diosgenin is used in the pharmaceutical industry as the main precursor in the synthesis of
steroids [83]. It has the ability to penetrate cell membranes and bind to specific receptors [84]. Steroidal
sapogenins are bioactive molecules that have shown exceptional antiproliferative activity against several
human cancer cells. By making specific changes in the steroidal structure of diosgenin, it can affect its
biological activity. In a recent report, using diosgenin as the parent molecule, the authors synthesized
two novel steroidal oxime compounds that showed significant antiproliferative activity on cervical
cancer cells and human lymphocytes. These compounds induced apoptosis and activated caspase
3 [85]. In another study Mohammad et al., reported on the anti-proliferative activity of diosgenin
and its semi-synthetic derivatives against breast (HBL-100), colon (HCT-116 and HT-19) and lung
(A549) cancer cells. A structure-activity relationship study revealed that the potent anti-proliferative
activity was mainly attributed to the analogs with the simple phenyl R moiety or electron-withdrawing
ortho-substituted R moieties attached to the parent diosgenin [86]. In another study, diosgenin was
used as a parent compound to synthesize 1α-hydroxysolasodine; it showed significant anti-cancer
activity against prostate cancer (PC3), cervical carcinoma (HeLa), and hepatocellular carcinoma
(HepG2) cells [87]. Twelve different analogs of diosgenin containing a long chain fatty acid/ester
of diosgenin-7-ketoxime exhibited anti-cancer activity when tested against a panel of cancer cell
lines. Compound 16 in this series exhibited potent anti-proliferative activity against DU145 prostate
cancer cells, which was associated to the suppression of lipopolysaccharide-induced activation of
TNF-α and IL6. The compound was also identified as safe, with a maximum tolerated dose of
300 mg/kg in Swiss albino mice [88]. In a recent article by Ghosh et al., they reported the synthesis of
diosgenin functionalized iron oxide nanoparticles that exhibited anti-breast cancer activity by inhibiting
proliferation and migration, and by inducing apoptosis [89].
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6. Conclusions and Future Perspectives
Compounds derived either from medicinal or dietary plant sources embrace distinct advantages,
such as novel bioactive structures, low toxicity, and being multi-targeted in abrogating oncogenic
processes; thereby, they may form the source of improved therapeutic options. A vast body of pre-
clinical experimental evidence suggests that diosgenin has great potential as an anti-cancer agent.
In this review we have compiled and analyzed the role of diosgenin in modulating various oncogenic
transcription factors and intracellular molecular targets that drive tumor initiation, progression and
metastasis. It is well known that the majority of cancers are a consequence of chronic inflammation,
infection, dysfunctional cell death mechanisms, and deregulation of cell cycle molecules. The ability of
diosgenin to prevent carcinogenesis by acting as an anti-oxidant and anti-inflammatory agent, and its
ability to induce apoptosis of cancer cells, suggests that it can be useful as an anti-carcinogenic agent.
Due to the complexities in the cellular processes involved, several new studies need to be conducted to
decipher the exact molecular targets that can be exploited to prevent cancer progression. Interestingly,
there are 12 reported clinical trials on fenugreek seed extract on a variety of human ailments, as
reported in www.clinicaltrials.gov. However, to date, there are no cancer-related clinical trials reported
either on diosgenin or on fenugreek seed extract. Several novel synthetic diosgenin derivatives have
been shown to improve its anti-cancer efficacy. Several nano-formulations and delivery systems of
diosgenin are also shown to improve its bioavailability. In conclusion, several challenges such as
developing novel delivery systems, pharmaceutical formulations, and semi-synthetic derivatives that
are water soluble, need to be overcome to uncover diosgenin’s benefits either as a chemopreventive or
therapeutic agent.
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